T2 Biosystems makes in vitro diagnostic products that detect sepsis-causing pathogens directly from whole blood samples, without requiring a positive blood culture first. The company's core product is the T2Dx Instrument, a bench-top analyzer that accepts whole blood in a disposable cartridge and delivers results in 3–5 hours — compared to 1–5 days for blood culture, the current standard of care. The T2Dx runs multiple FDA-cleared test panels, including T2Bacteria (covering ~75% of bacterial bloodstream infections) and T2Candida (covering ~90% of Candida bloodstream infections). T2 Biosystems also sells a biothreat detection panel to U.S. and allied government agencies, and has a resistance panel targeting antimicrobial resistance genes pending FDA clearance. T2 Biosystems follows a razor-and-blade model: instruments are placed or sold to hospitals to build an installed base, and hospitals then purchase disposable test panel cartridges on a recurring basis. Cartridges are the primary revenue driver and carry high direct contribution margins. Revenue scales by expanding the installed base and increasing test utilization per instrument. T2 Biosystems sells directly to U.S. hospitals and through exclusive distributors internationally, with a global installed base approaching 200 instruments. The company is pre-profitability, with a small commercial organization and a pipeline of new panels — including T2Lyme and a Candida auris test — each designed to run on the existing T2Dx platform.